BRIEF published on 08/19/2024 at 13:05, 1 year 8 months ago Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05 FDA Approval Cancer Treatment Healthcare Innovation Biosimilar Neutropenia
BRIEF published on 08/19/2024 at 13:05, 1 year 8 months ago Tanvex BioPharma USA, Inc. franchit deux étapes réglementaires aux États-Unis : la FDA approuve Nypozi(TM) et la FDA accepte la demande de licence de produits biologiques biosimilaires pour le TX-05 Traitement Du Cancer Approbation De La FDA Biosimilaire Innovation Dans Le Domaine De La Santé Neutropénie
BRIEF published on 08/19/2024 at 12:50, 1 year 8 months ago Northern Dynasty: Alaska Court Grants Motion to Add USACE to Existing EPA Complaint Pebble Project Northern Dynasty Alaska Court EPA Complaint USACE Inclusion
BRIEF published on 08/19/2024 at 12:50, 1 year 8 months ago Northern Dynasty : Un tribunal de l'Alaska accorde une motion visant à ajouter l'USACE à la plainte existante de l'EPA Dynastie Du Nord Tribunal De L'Alaska Plainte Auprès De L'EPA Inclusion De L'USACE Projet Pebble
BRIEF published on 08/19/2024 at 12:40, 1 year 8 months ago Epique Realty Announces Strategic Expansion Into New Mexico and Utah Expansion Real Estate Innovative Approach William Lambert New Markets
BRIEF published on 08/19/2024 at 12:40, 1 year 8 months ago Epique Realty annonce une expansion stratégique au Nouveau-Mexique et dans l'Utah Expansion Immobilier William Lambert Nouveaux Marchés Approche Innovante
BRIEF published on 08/19/2024 at 12:35, 1 year 8 months ago Bénéteau : Transactions sur actions propres du 12 au 16 août 2024 Euronext Paris BENETEAU Transactions D'actions Marché Prix Pondéré
BRIEF published on 08/19/2024 at 12:35, 1 year 8 months ago Bénéteau: Transactions on own shares from August 12 to 16, 2024 Euronext Paris BENETEAU Stock Transactions Walk Weighted Price
BRIEF published on 08/19/2024 at 12:35, 1 year 8 months ago NanoViricides Advances Towards Phase II Trial of NV-387 NanoViricides NV-387 Antiviral Therapy Phase II Trial RSV, COVID, Influenza
BRIEF published on 08/19/2024 at 12:35, 1 year 8 months ago NanoViricides avance vers la phase II de l'essai du NV-387 NanoViricides NV-387 Essai De Phase II Thérapie Antivirale VRS, COVID, Grippe
Published on 04/30/2026 at 19:00, 1 hour 2 minutes ago Caldwell Announces Appointment of Shawn Banerji as Co-Leader of Technology Practice
Published on 04/30/2026 at 16:00, 4 hours 2 minutes ago CORRECTION FROM SOURCE: Rio Grande Resources Announces Results from its Airborne Survey at Winston Gold/Silver Project, New Mexico and Announces New President
Published on 04/30/2026 at 15:35, 4 hours 27 minutes ago Nepra Foods Enters Letter of Intent to Acquire Idaho Bottling and Water Assets, Advancing Vertical Integration Strategy
Published on 04/30/2026 at 15:10, 4 hours 52 minutes ago Formation Metals Announces Non-Brokered Offering of up to $15 Million Fully Allocated
Published on 04/30/2026 at 19:00, 1 hour 1 minute ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 1 hour 2 minutes ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 18:59, 1 hour 2 minutes ago Sirma Group Holding published its Invitation for Annual Regular General Shareholder Meeting
Published on 04/30/2026 at 18:45, 1 hour 17 minutes ago ENERGISME: Résultats annuels 2025 : Energisme a tenu tous ses engagements
Published on 04/30/2026 at 18:41, 1 hour 20 minutes ago Ørsted completes divestment of its European onshore business
Published on 04/30/2026 at 19:16, 46 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 hour 2 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 04/30/2026 at 19:00, 1 hour 2 minutes ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:15, 1 hour 47 minutes ago ALPOU - Groupe POULAILLON chiffre d'affaires S1 2025-2026 et focus sur les activités
